Oncology News Central Peer-Spectives
By Oncololgy News Central
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Oncololgy News Central
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 100
Description
Peer-Spectives is a podcast series that is moderated by Robert Figlin, MD, and features various oncology thought-leaders covering the latest clinical developments in a wide range of tumor types.
| Episode | Date |
|---|---|
|
Are Oral SERDs About to Transform Breast Cancer Care?
|
Jul 15, 2025 |
|
Game-Changers and Paradigm Shifts: ASCO 2025 Data Shake Up Breast Cancer Care
|
Jul 14, 2025 |
|
Practice-Changing Data in Colorectal Cancer Lead to Broader Questions in Oncology
|
Jul 11, 2025 |
|
Oncologist Faculty Burnout Caused by “Unrealistic” Expectations, Says ASCO CEO
|
Jul 08, 2025 |
|
After Years of Inactivity, “Dizzying” Changes Hit Bladder Cancer Care
|
Jul 07, 2025 |
|
Practice Changing or “Practice Confounding”? Pivotal Breast Cancer Data Raise Big Questions
|
Jul 03, 2025 |
|
NCCN CEO Discusses Guideline Updates, Other Key Initiatives
|
Jul 01, 2025 |
|
Former National Cancer Institute Director Discusses the Future of Cancer Care
|
Jun 24, 2025 |
|
Game-Changing Blood Cancer News at ASCO 2025: Rusfertide Shows Strong Benefit in Polycythemia Vera
|
Jun 20, 2025 |
|
Getting Americans to Support Cancer Research May Take a New Message, Oncology Leader Says
|
Jun 18, 2025 |
|
“Important Milestone”: Perioperative Durvalumab Improves Event-Free Survival in Gastric Cancer
|
Jun 17, 2025 |
|
What Does the Biggest News in Breast Cancer From ASCO 2025 Mean for Practice Right Now?
|
Jun 12, 2025 |
|
Practice-Changing “Inflection Point” Coming in ESR1-Positive Breast Cancer Care?
|
May 29, 2025 |
|
When ESR1 Mutations Arise in Breast Cancer Patients With PIK3CA Mutations: What Next?
|
May 06, 2025 |
|
How “Remarkable Change” in EGFR-Mutated NSCLC Care Is Making a Difference for Patients
|
Apr 21, 2025 |
|
Oncologists Urged to Discuss Fertility With Patients, as ASCO Updates Guidelines
|
Apr 17, 2025 |
|
“Second-Line ER-Positive Breast Cancer Has Just Become Very Complicated”
|
Apr 15, 2025 |
|
Will Generational Divide Among Oncologists Affect How AI Changes Cancer Care?
|
Apr 07, 2025 |
|
“Time to Move On”: How Targeted Therapies Are Transforming AML Care
|
Mar 31, 2025 |
|
ASCO President Speaks Out on “Huge Problem” of Oncologist Burnout
|
Feb 27, 2025 |
|
Oncologists Overtreat Patients at End of Life
|
Jan 29, 2025 |
|
FDA Approvals Change Practice for Metastatic Breast Cancer With PIK3CA Mutations
|
Dec 16, 2024 |
|
To Help Oncologists’ Burnout, Should Primary Care Take on More Burden?
|
Nov 13, 2024 |
|
Choosing Between an “Old Friend” and New Ones in EGFR-Mutated Metastatic NSCLC
|
Nov 08, 2024 |
|
Privatization of Cancer Clinical Research Raises Concerns for Practice
|
Nov 04, 2024 |
|
What 3 Big Trials Mean for Breast Cancer Practice
|
Oct 28, 2024 |
|
“Confusing for All of Us”: Questions Arise Over ADCs, HER2 in Metastatic Breast Cancer
|
Oct 21, 2024 |
|
”Where Do We Go From Here?” Targeted Therapies Lead to Challenging Choices in Breast Cancer
|
Sep 27, 2024 |
|
After Practice Change in Unresectable Stage III NSCLC, Questions Remain
|
Aug 29, 2024 |
|
What ”Incredibly Dramatic” Data on Osimertinib in NSCLC Mean for Practice
|
Aug 28, 2024 |
|
“Smart Bombs” Upend Breast Cancer Care: What Oncologists May Not Know About Antibody-Drug Conjugates
|
Aug 22, 2024 |
|
Oncology Must Do More for Long-Term Cancer Survivors, Expert Says
|
Aug 13, 2024 |
|
“A Good, Peaceful Death” From Cancer: Oncologists Must Be Part of “National Dialogue”
|
Jul 31, 2024 |
|
FDA Approvals in Relapsed/Refractory CLL Set up ”Difficult Choice”
|
Jul 24, 2024 |
|
Oncologists Struggling With Cancer Deaths Among Millennial Patients
|
Jul 24, 2024 |
|
Top Lung Cancer Data From ASCO 2024 Should Change Practice “Immediately,” Experts Agree
|
Jul 08, 2024 |
|
What Were the Biggest Data at ASCO 2024 in Kidney Cancer?
|
Jul 05, 2024 |
|
What New “Elephant in the Room” Means for Bladder Cancer Care
|
Jul 03, 2024 |
|
Immunotherapy in “Hardest Stage” of NSCLC: Putting Recent Advances Into Practice
|
Jul 02, 2024 |
|
”We’re Past the Inflection Point,” as ”Massive Change” Hits Breast Cancer Care
|
Jul 01, 2024 |
|
To Get Better Cancer Drugs Faster, Is It Time for an “International FDA”?
|
Jun 26, 2024 |
|
”Very Important” Myeloma Data: ASCO Highlights, Smoldering Challenges, and More
|
Jun 20, 2024 |
|
Durvalumab’s Benefit in SCLC ”Beyond What We Might Have Expected”
|
Jun 17, 2024 |
|
New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers ”Fantastic” Potential, Expert Says
|
Jun 13, 2024 |
|
Should All Breast Cancer Patients Get T-DXd? ”Results of DESTINY-Breast06 Do Suggest That”
|
Jun 10, 2024 |
|
Oncologist Shortage “Has Gotten to the Crisis Level”
|
May 06, 2024 |
|
“Monster Improvements” in CLL Care Prompt Questions About BTK Inhibitor Use
|
Apr 16, 2024 |
|
“Better to Have Choices”: How New Data Transform EGFR-Mutated NSCLC Care
|
Mar 29, 2024 |
|
Practice-Changing Data Introduce “Whole New Challenge” in Prostate Cancer
|
Mar 26, 2024 |
|
FDA Approval for TIL Therapy “Real Milestone” That Has Been “Long Time Coming”
|
Mar 21, 2024 |
|
From “Fairytale” to Reality? Paradigm Shift in Bladder Cancer Care
|
Mar 08, 2024 |
|
FDA Approvals, Pivotal Trial Data Change Approach to Breast Cancer Progression
|
Feb 14, 2024 |
|
Controversies, Difficult Questions Arise in NSCLC Amid New Data
|
Feb 12, 2024 |
|
What FDA Approval of Belzutifan Means for Kidney Cancer Care
|
Feb 05, 2024 |
|
Despite Lack of Head-to-Head Trials, Practice Patterns Shifting in Breast Cancer
|
Feb 01, 2024 |
|
Which FDA Approvals, Other Advances Changed ER-Positive Breast Cancer Care in 2023?
|
Dec 18, 2023 |
|
“New Disruptor” in Prostate Cancer: PSMA PET and Other Treatment Advances
|
Dec 15, 2023 |
|
Practice-Changing Results in Prostate Cancer, as Enzalutamide Regimens Show Strong Benefit
|
Dec 14, 2023 |
|
ER-Positive Breast Cancer Advances and Other Eagerly Anticipated Data at SABCS 2023
|
Nov 20, 2023 |
|
Inside ODAC’s Vote on Sotorasib in Advanced and Metastatic NSCLC: Lessons Learned
|
Nov 15, 2023 |
|
First-Line Osimertinib Plus Chemo in NSCLC: How to Weigh Toxicity vs. Efficacy
|
Nov 07, 2023 |
|
What Recent “Outstanding Results” in MCL Mean for Practice
|
Oct 27, 2023 |
|
The Quest to Cure CLL: “Remarkable” Results With New Strategy
|
Sep 06, 2023 |
|
Which Data From the 2023 World Conference on Lung Cancer Are Most Likely to Change Practice?
|
Aug 15, 2023 |
|
“Really Impactful” New Guidelines for Stage IV NSCLC With Driver Alterations
|
Aug 03, 2023 |
|
More “Cage Rattling,” Less Talking: Susan Love’s Lessons for Oncologists
|
Jul 18, 2023 |
|
Will HER3 Targeting Change Breast Cancer Care?
|
Jun 27, 2023 |
|
“Practice-Expanding” Data on Adjuvant Osimertinib in NSCLC: Steps to Take Now
|
Jun 26, 2023 |
|
“Don’t Just Throw Drugs Together”: How to Best Approach ESR1 Mutations in Breast Cancer
|
Jun 20, 2023 |
|
mRNA Cancer Vaccines: When to Expect FDA Approval, and What’s Next?
|
May 17, 2023 |
|
“Major Wins” in Lung Cancer Treatment: How “Explosion of Data” Is Changing Practice
|
May 09, 2023 |
|
“Great Therapies for All-Comers” in CLL: How Can Oncologists “Pick and Choose?”
|
Apr 18, 2023 |
|
Pragmatica-Lung Tests a Treatment and a New Approach to Trials
|
Mar 17, 2023 |
|
The Best First Step in Metastatic NSCLC Care
|
Mar 10, 2023 |
|
Neo- and Adjuvant Treatments Are Changing Care in Early NSCLC
|
Mar 06, 2023 |
|
NALIRIFOX Changes Care in Pancreatic Cancer: Here’s How
|
Feb 16, 2023 |
|
Matching Breast Cancer Patients to Therapies: Here’s How
|
Dec 16, 2022 |
|
Myelofibrosis Remains Tough to Treat, But New Drugs Are Paving the Way
|
Nov 11, 2022 |
|
KRAS Inhibition in NSCLC: When, How, and Why?
|
Nov 11, 2022 |
|
Strategies for Navigating a Hematology/Oncology Fellowship
|
Nov 04, 2022 |
|
Taking Aim at MET and KRAS in NSCLC
|
Oct 29, 2022 |
|
Mantle Cell Lymphoma: Optimizing Current Therapies
|
Oct 28, 2022 |
|
COSMIC-313 trial and the Complex Treatment Landscape for Metastatic Renal Cell Cancer: How Do You Decide?
|
Oct 19, 2022 |
|
Finding Joy in Work: ASCO’s Career Development Resources Help Trainees Choose Their Path
|
Oct 04, 2022 |
|
Considering an Oncology Fellowship? Listen to This First
|
Sep 06, 2022 |
|
Kidney Cancer at a Crossroads: What New Trial Results Could Mean for Patients
|
Aug 19, 2022 |
|
How to Choose CLL Treatments in the Frontline Setting
|
Jul 08, 2022 |
|
Rethinking HER2-Targeted Therapy After DESTINY-04
|
Jul 07, 2022 |
|
Most Patients with BRAF-mutant Metastatic Melanoma Benefit from First-line Immunotherapy
|
Jun 16, 2022 |
|
Adjuvant and Neoadjuvant Therapy for NSCLC: Who to Treat and With What Agent
|
May 05, 2022 |
|
The Complex Decisions in CLL Treatment Today: Clarifying the Choices
|
Apr 13, 2022 |
|
DREAMseq Trial: What It Means for Metastatic Melanoma Treatment
|
Mar 29, 2022 |
|
The Latest Thinking Regarding Adjuvant Pembrolizumab in Renal Cell Carcinoma Post-ASCO GU ‘22
|
Mar 11, 2022 |
|
Post ASCO GU ’22 – Muscle-Invasive Bladder Cancer, EV-103, Enfortumab Vedotin, and the Clinical Progress Being Made Managing MIBC Patients
|
Mar 07, 2022 |
|
The HIMALAYA Study Presented at ASCO GI ’22: An Update on the State of Liver Cancer Treatment Today
|
Jan 26, 2022 |
|
Frederick Locke, MD of Moffit Cancer Center and Robert Figlin, MD of Cedars-Sinai discuss ZUMA-7, the role of CAR-T in the management of relapsed/refr...
|
Dec 22, 2021 |
|
From SABCS ’21: Neoadjuvant Immunotherapy and the Use of the 21-Gene Signature Test
|
Dec 14, 2021 |
|
Targeted Therapy and Venclexta Combinations for AML and a Look Ahead to ASH ’21
|
Dec 02, 2021 |
|
After CodeBreaK100:
|
Nov 20, 2021 |
|
ESMO ’21: The ARCHES Study and Progress in Metastatic (and Non-Metastatic) Hormone-Sensitive Prostate Cancer
|
Sep 22, 2021 |